Mifepristone Dosing Optimization for Cushing's Syndrome

Solution Overview

Problem

The administration of mifepristone results in widely varying blood serum levels among patients, leading to some not receiving an efficacious dose, particularly for those with Cushing's syndrome who require higher levels for therapeutic response.

Innovation Solution

A method involving the administration of seven or more daily doses of mifepristone over seven or more days, followed by serum level testing and dose adjustment to maintain levels greater than 1631 ng/mL, specifically tailored for patients with Cushing's syndrome.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If the same dose of mifepristone is administered to all patients, then the treatment process is simple and standardized, but the blood serum levels vary widely leading to insufficient therapeutic effect in some patients

Engineering Contradiction:
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent applies parameter changes by adjusting the mifepristone dose based on individual patient characteristics (body weight, Cushing's syndrome severity) and monitoring blood serum levels to achieve the therapeutic threshold of 1631 ng/mL. This transforms the fixed-dose approach into a flexible, personalized dosing strategy that maintains reliability while adapting to individual patient needs.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If higher doses of mifepristone are administered to ensure therapeutic levels, then therapeutic efficacy is improved, but the risk of adverse effects and toxicity increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent implements feedback control through therapeutic drug monitoring (TDM) of mifepristone blood serum levels. By measuring actual serum concentrations and comparing them to the therapeutic threshold of 1631 ng/mL, the system provides feedback that guides dose adjustments. This closed-loop approach ensures sufficient therapeutic levels are achieved while avoiding excessive dosing that would increase adverse effects.

Inventive Principle:
Principle #23Feedback

3Reliability

If individualized dosing based on serum level monitoring is implemented, then therapeutic efficacy is optimized, but the complexity of the treatment process increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by establishing clear dosing guidelines and therapeutic thresholds (1631 ng/mL) before treatment begins. The protocol pre-specifies dosing ranges, monitoring schedules, and adjustment criteria based on body weight and clinical presentation. This preparation reduces the complexity during actual treatment execution, as clinicians follow predetermined algorithms rather than making complex decisions in real-time.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS11173165B2Optimizing mifepristone levels for Cushing's patients
Publication Date: 2021.11.16
  • US11173165B2 patent drawing

AI summary

The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.